Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acapatamab (AMG 160) in Advanced Non-Small Cell Lung Cancer
NCT04822298Phase 1Terminated
- Sponsor
- Amgen
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of acapatamab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicities and Treatment-Emergent Adverse Events. Started Aug 2021; status: terminated.
02
Drugs
acapatamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04822298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822298.